Inflammatory bowel disease (IBD) is a chronic, relapsing intestinal disorder with heterogeneous clinical phenotypes and variable therapeutic outcomes, and it is highlighted as a setting with drug-development attrition exceeding 85%. It is strongly linked to the gut microbiota, and current work emphasizes gut microbiota-based diagnostics, multi-omics, and metabolomics to improve disease classification and detection. Traditional clinical biomarkers such as c reactive protein and fecal calprotectin remain in use, while newer approaches integrate molecular measures and AI-based assessments with clinical end points. Disease modeling and translational testing are supported by human intestinal organoids and patient derived intestinal organoids, which are being positioned for preclinical and clinical drug development. Therapeutically, selective IL-23 inhibition has shown clinical efficacy in IBD, and in mouse models vbit 12 protected against apoptosis, pyroptosis, ferroptosis, and associated pathologies. Recent literature also points to multimodal deep learning for diagnosis, monitoring, and personalized care, underscoring the move toward precision medicine in IBD.
Diagnostics and Biomarkers
- Multidimensional microbiota-based approaches were proposed for diagnosing IBD, reflecting the disease’s strong microbiome component. (PMID:41220286)
- Microbiome and metabolomic data integration improved diagnostic accuracy for IBD, supporting multi-omics-based classification. (PMID:41220286)
- Traditional biomarkers c reactive protein and fecal calprotectin were described as standard clinical tools for IBD diagnosis. (PMID:41665578)
- Multimodal deep learning was presented as a route to biomarker discovery and clinical translation in IBD. (PMID:41857729)
- Integration of molecular measures and AI-based assessments with clinical end points was discussed as a framework for IBD evaluation. (PMID:41665578)
Therapeutics and Disease Mechanisms
- Selective IL-23 inhibition demonstrated clinical efficacy in IBD, including ulcerative colitis. (PMID:41871904)
- In IBD mouse models, vbit 12 protected against apoptosis, pyroptosis, ferroptosis, and disease-associated pathologies. (PMID:41964801)
- The VDAC1-targeting study linked mitochondria-associated cell death pathways to inflammatory disease mechanisms relevant to IBD. (PMID:41964801)
- IBD was cited as an example of a complex disorder with early clinical trial attrition above 85%, highlighting therapeutic development challenges. (PMID:41766415)
Models and Translational Platforms
- human intestinal organoids were discussed as disease models relevant to intestinal diseases including IBD. (PMID:41766415)
- patient derived intestinal organoids were presented as translational models for preclinical and clinical drug development in intestinal disease contexts. (PMID:41766415)
- Organoid-based approaches were framed within FDA new approach methodologies for drug discovery, supporting more predictive IBD testing. (PMID:41766415)
- Multiomic characterization of guselkumab induction therapy in ulcerative colitis provided a clinical-translational example of precision assessment in IBD. (PMID:41871904)